Press Room

News / Sep 23, 2019

Hovione is a Best For The World 2019 Honoree

The Best For The World lists are determined based on the verified B Impact Assessments of Certified B Corporations

Best For The World Company 2019 | Hovione

Every year, B Lab recognizes the top-performing Certified B Corporations around the world. For the second year in a row, Hovione is in the top 10% list of all B Corps that are best for Customers.

As an honoree, Hovione are a top-performing B Corp proving that competing not only to be best in the world but best for the world is a winning strategy.

Hovione has earned a place on the 2019 Best for the World list by scoring in the top 10 percent among all B Corps on the B Impact Assessment. Best for the World lists are segmented by:

  • Best Overall
  • Best for Workers
  • Best for Communities
  • Best for the Environment
  • Best for Customers
  • Best for Governance

We recall that in last June 2017 Hovione became a Certified B Corp at the B Corp Summer Summit.

Hovione was the first Chemical/Pharmaceutical Company to integrate this innovative community of companies that use the power of business to solve social an environmental problems.

 

 

 

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024